Actively Recruiting
Syndromes With Neonatal Salt Loss: Not Only Congenital Adrenal Hyperplasia Due to 21-hydroxylase Deficiency (21OH-ISC)
Led by IRCCS Azienda Ospedaliero-Universitaria di Bologna · Updated on 2026-03-16
25
Participants Needed
1
Research Sites
89 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Neonatal salt loss can be caused not only by infections but also by rare endocrine disorders that resemble 21-hydroxylase deficiency but are not detected by neonatal screening. This study examines how often these conditions occur and describes their main clinical, genetic, and treatment features.
CONDITIONS
Official Title
Syndromes With Neonatal Salt Loss: Not Only Congenital Adrenal Hyperplasia Due to 21-hydroxylase Deficiency (21OH-ISC)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosis of endocrine-related salt loss with hyponatremia (serum sodium <130 mEq/L)
- Salt loss onset between 0 and 60 days of life
- Born between January 1, 1989 and December 31, 2023
- Managed at the Experimental Center
- Informed consent obtained
You will not qualify if you...
- Diagnosis of 21-hydroxylase deficiency (21OH ISC)
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Bologna, Italy, 40138
Actively Recruiting
Research Team
F
Federico Baronio
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here